Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Castle Biosciences' DecisionDx-Melanoma test and Revolution Medicines' elironrasib cancer drug receive FDA Breakthrough ...

Combining Scancell's melanoma drug iSCIB1+ with Yervoy and Opdivo significantly improved patient overall response rate.

Neoadjuvant immunotherapy is associated with high rates of event-free survival in patients with resectable melanoma.

Medicare data show older women with vulvar lichen sclerosus are over 11 times more likely to develop vulvar squamous cell ...

WWE Hall of Famer Ric Flair is cancer free once again. Flair announced on Tuesday that he's completed his treatment for melanoma. Per TMZ, it was his second battle with skin cancer within the last ...

The wrestling icon announced in June that he would begin treatment for the issue following his second diagnosis in three ...

Florida Gov. Ron DeSantis, First Lady Casey DeSantis, Florida Department of Health Surgeon General Dr. Joseph Ladapo and ...

Iova stock jumps 31% amid FDA setback for rival, short squeeze buzz, and rising momentum for Amtagvi melanoma therapy.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...

According to Research by SNS Insider, U.S. Basal Cell Carcinoma Treatment Market Growth is Driven by Aging Population and Technological Advancements in Dermatological Care.Austin, July 23, 2025 (GLOBE ...